Bariatric injection pills

World Health Adjust Guidelines for the Use of "Bariatric Injection Drugs"

LA (Siam Town US): WHO issues new "Guidelines" for the GLP-1 family of bariatric injection drugs, including hit injection drugs like "Osimpik."

On December 8, 2025, The Hill reported that the World Health Organization (WHO) has issued new recommendations on the use of GLP-1 drugs such as Ozempic, Wegovy, Mounjaro and Zepbound to treat obesity, which is becoming a major global problem.

News says that in 2024, it estimates that about 12.5 percent of adult GLP-1 users use it to lose weight, and that the number of people using it for this purpose will increase further this year.

GLP-1 is a diabetes drug, but it has the side effect of stimulating hormones that affect appetite, making users feel fuller. The Food and Drug Administration has accepted its use as an obesity drug since 2021.

There are two new WHO recommendations. The first states that GLP-1 can be used to treat obese adults except pregnant women, and the second is to emphasize that GLP-1 is not an inclusive solution, suggesting that users consider using it in tandem with other measures such as dietary modification and intensive exercise, along with drug use.

The two main proposals are conditional recommendations. This means that they are not forced to be implemented in all cases, but depending on the circumstances or context of the user, because there is limited information about the long-term effects, including information about what will happen when the drug is stopped.

However, Dr Francesca Zeletti, a senior adviser on obesity at the World Health Organization, said while proposing the new approach that "medicine alone cannot solve the problem," citing research that users of GLP-1 drugs, to reduce obesity, need to obtain full nutrition, including exercise, because GLP-1 drugs can cause users to lose muscle mass.

"We should not neglect what needs to be done, nor should we deceive ourselves that one drug can be used to solve this problem," said Dr. Seletti.

The cost of continued use is also discussed, with the news saying that GLP-1, mostly injected once a week, costs a month of "hundreds of dollars."